Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Year: 2012
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Authors: Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber-Bodéré, Veronique Dieras, Max E. Scheulen, Avinash Gupta, Vanesa Lopez-Valverde, Zhi-Xin Xu, Ruediger Rueger, Jean J.L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jan H.M. Schellens, Wilfried Ernst Erich Eberhardt
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funders: Roche, Chugai Pharmaceutical
OpenAlex ID: W2130979878
